CervoMed Inc. Reports Q3 2026 Financial Results and Liquidity Update

CervoMed Inc. reported a narrower net loss in Q3 2026, driven by lower operating expenses, and said grant revenue has ended. The company stated that its cash resources are insufficient to fund operations for the next 12 months. Starting a Phase 3 trial for its dementia with Lewy bodies program depends on securing additional funding or a strategic partnership.